← Russell 3000 cross-section

NUVB Nuvation Bio Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$2.4bn
Revenue TTM
$170m
Net income TTM
$-150m
Free cash flow
Composite score
Sector rank
#1530

Valuation

P / E
EV / EBITDA
EV / sales
11.9
FCF yield
Earnings yield vs 10-yr
-10.90pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-88.2%
EBITDA margin
ROE
-59.0%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-2.01m
Buyers
1
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Components of Results of Operations Revenue Prior to our commercialization of IBTROZI, substantially all of our revenue was generated from payments under prior collaboration agreements, and milestones, royalties and other revenue from our licensing arrangements. Net product revenue from U.S. sales of IBTROZI was approximately $23.2 million and $41.7 million for the three and six months ended June 30, 2026, respectively. Collaboration and License Agreements Revenue Collaboration and license agreements revenue increased by $4.9 million for the three months ended June 30, 2026 compared to 2025. …Nuvation Bio Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →